Analysts Offer Insights on Healthcare Companies: Xoma Corp (NASDAQ: XOMA), Acelrx (NASDAQ: ACRX) and CytoDyn Inc (Other OTC: CYDY)

By Jason Carr

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Xoma Corp (XOMAResearch Report), Acelrx (ACRXResearch Report) and CytoDyn Inc (CYDYResearch Report) with bullish sentiments.

Xoma Corp (XOMA)

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Xoma Corp, with a price target of $30. The company’s shares closed yesterday at $13.02, close to its 52-week low of $11.02.

According to TipRanks.com, Pantginis has 0 stars on 0-5 star ranking scale with an average return of -10.7% and a 31.3% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Checkpoint Therapeutics Inc, and Iovance Biotherapeutics Inc.

Currently, the analyst consensus on Xoma Corp is a Moderate Buy with an average price target of $31.

See today’s analyst top recommended stocks >>

Acelrx (ACRX)

In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Acelrx, with a price target of $9. The company’s shares closed yesterday at $3.38.

Arce said:

“We project U.S. peak sales of $325M in 2026 for DSUVIA. For Zalviso, we project product launch in 1H20 (85% POS) with peak sales in 2027 of about $185M. We apply a 12.5% discount rate to both products.”

According to TipRanks.com, Arce is a 5-star analyst with an average return of 13.4% and a 44.9% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Arcturus Therapeutics Ltd, and Melinta Therapeutics Inc.

Currently, the analyst consensus on Acelrx is a Strong Buy with an average price target of $8.50.

CytoDyn Inc (CYDY)

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on CytoDyn Inc today and set a price target of $1.50. The company’s shares closed yesterday at $0.45.

Selvaraju noted:

“Our 12-month price target is derived from an estimated market value of the firm at $560M. It includes a discounted cash flow-based asset value of $566M for leronlimab in the HIV indication alone, with a 15% discount rate, 2% terminal growth rate, 80% probability of success, and excluding $6M debt. Assuming 375M shares outstanding at the end of February 2020, this translates to a per share value of approximately $1.50.”

According to TipRanks.com, Selvaraju is a 3-star analyst with an average return of 1.5% and a 39.5% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.

CytoDyn Inc has an analyst consensus of Moderate Buy, with a price target consensus of $1.50.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.